The decision reflects CHOSA’s commitment to building a long-term presence in the United States as it advances the market launch of its proprietary biomarker platform.

“Establishing a US presence is an important milestone for CHOSA and reflects our commitment to bringing Platin-DRP to the US market,” says Peter Buhl Jensen, CEO of CHOSA Oncology. “Boston and Kendall Square offer unparalleled access to leading oncology researchers, diagnostic laboratories, pharmaceutical companies, and investors. By establishing operations in this ecosystem, we strengthen our ability to build the partnerships and infrastructure needed to support the future commercialization of Platin-DRP in the United States.”

CHOSA is currently preparing a stepwise US market entry for Platin-DRP, initially making the test available for Research Use Only (RUO) to researchers, pharmaceutical companies, and clinical collaborators.